Cargando…

Salvage Treatment with Cefiderocol Regimens in Two Intravascular Foreign Body Infections by MDR Gram-Negative Pathogens, Involving Non-Removable Devices

INTRODUCTION: The objective of this study was to describe two challenging cases of intravascular foreign body infections caused by multidrug-resistant Gram-negative pathogens requiring complex antimicrobial regimens including cefiderocol and successfully treated without implant removal. METHODS: Cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bodro, Marta, Hernández-Meneses, Marta, Ambrosioni, Juan, Linares, Laura, Moreno, Asunción, Sandoval, Elena, Olivas, Pol, Hernández-Tejero, María, Miró, José M., Marco, Francesc, Soriano, Alex
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955010/ https://www.ncbi.nlm.nih.gov/pubmed/33417231 http://dx.doi.org/10.1007/s40121-020-00385-4

Ejemplares similares

719. Cefiderocol Retains Anti-Biofilm Activity in MDR Gram-Negative Pathogens
por: Pybus, Christine A, et al.
Publicado: (2019)

Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections
por: Gavaghan, Victoria, et al.
Publicado: (2022)

Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series
por: Fendian, Ángel Marcos, et al.
Publicado: (2023)

Cefiderocol
por: Soriano, María Cruz, et al.
Publicado: (2022)

Mechanism of action of cefiderocol
por: Soriano, Alex, et al.
Publicado: (2022)

Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

P35 Heteroresistance to cefiderocol in clinical Gram-negative isolates
por: Watson, Celeste, et al.
Publicado: (2023)

Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens
por: Pybus, Christine A., et al.
Publicado: (2021)

Performance evaluation of the UMIC(®) Cefiderocol to determine MIC in Gram-negative bacteria
por: Dortet, Laurent, et al.
Publicado: (2023)

Mycobacterium Wolinskyi: A New Non-Tuberculous Mycobacterium Associated with Cardiovascular Infections?
por: Hernández-Meneses, Marta, et al.
Publicado: (2021)

Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
por: Bodro, Marta, et al.
Publicado: (2021)

Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
por: Wu, Janet Y., et al.
Publicado: (2020)

Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria
por: Wang, Yifan, et al.
Publicado: (2022)

Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria
por: Silva, José Tiago, et al.
Publicado: (2021)

COVID-19, rejection, and cutaneous mucormycosis in a long-term liver transplant recipient – the vicious cycle of immunosuppression and opportunistic infections
por: Pagano, Giulia, et al.
Publicado: (2022)

The effect of varying multidrug-resistence (MDR) definitions on rates of MDR gram-negative rods
por: Wolfensberger, Aline, et al.
Publicado: (2019)

Perioperative prophylaxis with ertapenem reduced infections caused by extended-spectrum betalactamase-producting Enterobacteriaceae after kidney transplantation
por: Sanclemente, Gemma, et al.
Publicado: (2019)

Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19
por: Meira, Fernanda, et al.
Publicado: (2021)

Treatment of Infections Due to MDR Gram-Negative Bacteria
por: Bassetti, Matteo, et al.
Publicado: (2019)

P24 Cefiderocol activity against a multidrug-resistant (MDR) strain of Pseudomonas aeruginosa: a case report
por: Lim,, Felicia H., et al.
Publicado: (2022)

Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria
por: Palombo, Marta, et al.
Publicado: (2023)

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria
por: Ito, Akinobu, et al.
Publicado: (2017)

In Vitro Activity of Cefiderocol against Multi-Drug Resistant Carbapenemase-Producing Gram-Negative Pathogens
por: Boyd, Sandra, et al.
Publicado: (2017)

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria
por: Mushtaq, Shazad, et al.
Publicado: (2020)

In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
por: Yamano, Yoshinori
Publicado: (2019)

Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2020)

648. Cefiderocol as Rescue Therapy for Pseudomonas aeruginosa and Other Difficult-To-Treat Gram-Negative Infections
por: Chou, Andrew, et al.
Publicado: (2022)

2811. Real-World Experience Utilizing Cefiderocol for Serious Multidrug Resistant Gram-Negative Infections
por: Teran, Nicholas S, et al.
Publicado: (2023)

Epidemiological Changes and Improvement in Outcomes of Infective Endocarditis in Europe in the Twenty-First Century: An International Collaboration on Endocarditis (ICE) Prospective Cohort Study (2000–2012)
por: Ambrosioni, Juan, et al.
Publicado: (2023)

Early appropriate diagnostics and treatment of MDR Gram-negative infections
por: Bassetti, Matteo, et al.
Publicado: (2022)

Complex endovascular retrieval of an intravascular foreign body
por: Kim, Tanner I., et al.
Publicado: (2021)

Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects
por: Saisho, Yutaka, et al.
Publicado: (2018)

1375. In vitro Activity of Cefiderocol and Comparator Agents against Gram-Negative Isolates from Cancer Patients
por: Rolston, Kenneth V I, et al.
Publicado: (2018)

Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
por: Katsube, Takayuki, et al.
Publicado: (2016)

721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City
por: Iregui, Alejandro, et al.
Publicado: (2019)

Comparison of Agar Dilution to Broth Microdilution for Testing In Vitro Activity of Cefiderocol against Gram-Negative Bacilli
por: Albano, Mariana, et al.
Publicado: (2020)

Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence
por: Wang, Chuanhai, et al.
Publicado: (2022)

P43 In vitro activity of cefiderocol and comparators against Gram-negative pathogens: ARTEMIS study in the UK
por: Wareham, D., et al.
Publicado: (2022)

1308. Activity of Cefiderocol and Comparators against Gram-negative Isolates from US Patients Hospitalized with Pneumonia
por: Shortridge, Dee, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gnufcd0eod7om5444rb3ika9bv